Corneal edema is refer to a cornea that is excessively hydrated than the normal 78% water content. Excess hydration of cornea causes to loss transparency of cornea and leads to impaired vision and eye pain. The corneal edema treatment choice is depends on the specific cause and related symptoms of an individual patient.
Elimination of the underlying aetiology must be targeted in the case of secondary edema (inflammation, infection, trauma, glaucoma). Topical corticosteroids and hypertonic agent are considered to be primary treatment therapies.
Topical corticosteroids reduces anterior segment inflammation and consequently corneal edema. Other complications is increase in intraocular pressure, which can be treated using hypertonic agent, carbonic anhydrase inhibitors.
Antibiotic therapies can be preferred in case of infection based corneal edema. For management of primary corneal edema, hypertonic agent in the form of topical drops and ointment can be prefer to treat mild edema which draw out excessive corneal fluid. In addition, bandage contact lens on cornea can be used as an auxiliary treatments to provide relief from discomfort of edema when surgical intervention is not recommended or is delayed.
In case of high-risk chronic corneal edema, surgical corneal transplantation treatment can be performed to improve vision of the patient.
Corneal edema treatment market is expected to witness high growth owing to increasing aging population and rise in eye disease prevalence. From patient perspective, increasing clinical research and subsequent new product launch is expected to fuel the corneal edema treatment market.
Increasing number of corneal trauma from cataract surgeries and accidents is a major driving factor of corneal edema treatment market. However, low healthcare expenditure are expected to hamper the future corneal edema treatment market in developing economies. Also, less awareness among the patient about the treatment option may deter the progress of corneal edema treatment market.
The global corneal edema treatment market is estimated to grow steady growth over forecast years owing to global rise in aging populations, increasing number of surgical procedures associated with eye disease epidemic. According to WHO, glaucoma is second leading cause of blindness globally which needs corneal edema prone surgical procedures.
In corneal treatment market, topical corticosteroids and hypertonic agents therapies are expected to grow with high rate owing to their use in first-line treatment in acute as well chronic conditions of corneal edema. Recently, DEXTENZA, a dexamethasone corticosteroid containing advanced delivery ophthalmic insert manufactured by Ocular Therapeutics is approved by US FDA.
However, corneal devices and transplantations associated post use/surgery risk is hampering their preference in treatment options.
The global corneal edema treatment market is expected to be dominated by North America due to higher product research and development activities with existing product availability. Europe is expected to be the second most growing region in the global corneal edema treatment market owing to advancements in early diagnosis and treatment.
Latin America is emerging region for corneal edema treatment market and is estimated to show exponential growth owing to high product availability. East-Asia corneal edema treatment market is expected to show significant growth as high prevalence. Middle East & Africa is expected to be the least lucrative region in the corneal edema treatment market due to least product adoption and standard diagnosis and treatment seeking rate.
The key players operating in the global corneal edema treatment market are: Pfizer Inc., Abbvie Inc, Novartis, Hoffmann-La Roche Ltd., Allergan, Bayer AG, Bausch & Lomb Incorporated, Johnson & Johnson, Teva Pharmaceuticals, Sun Pharmaceutical and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global corneal edema treatment market is segmented on the basis of drug class, indication, distribution channel, and region.
Based on the drug class, the global corneal edema treatment market is segmented as:
Based on indication, the global corneal edema treatment market is segmented as:
Based on form, the global corneal edema treatment market is segmented as:
Based on the distribution channel, the global corneal edema treatment market is segmented as:
Explore Similar Insights
Corneal Edema Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
